Background: Transient Receptor Potential (TRP) channels are expressed in many solid tumors. However, their expression in breast cancer remains largely unknown. Here, we investigated the profile expression of 13 TRP channels in human breast ductal adenocarcinoma (hBDA) and performed a correlation between their overexpression and pathological parameters. Methods: The TRP channels expression was determined by RT-PCR in hBDA tissue, in human breast cancer epithelial (hBCE) primary culture and in MCF-7 cell line. The TRP protein level was evaluated by immunohistochemistry in hBDA tissue samples of 59 patients. Results: TRPC1, TRPC6, TRPM7, TRPM8, and TRPV6 channels were overexpressed in hBDA compared to the adjacent non-tumoral tissue. Most interestingly, TRPC1, TRPM7 and TRPM8 expression strongly correlated with proliferative parameters (SBR grade, Ki67 proliferation index, and tumor size), and TRPV6 was mainly overexpressed in the invasive breast cancer cells. Using laser capture microdissection, we found that TRPV6 expression was higher in invasive areas, compared to the corresponding non-invasive ones. Moreover, TRPV6 silencing inhibited MDA-MB-231 migration and invasion, and MCF-7 migration. Conclusion: TRP channels are aberrantly expressed in hBDA, hBCE primary cultures, and cell lines, and associated with pathological parameters. The high expression of TRP channels in tumors suggests the potential of these channels for diagnostic, prognosis and/or therapeutic approaches in human breast ductal adenocarcinoma.
Introduction
Breast cancer is the leading cancer occurring in women in terms of incidence and mortality [1] . Recent studies have underlined the involvement of ion channels such as potassium channels in cell cycle progression and migration [2] [3] [4] , as well as sodium channels in invasion processes [5, 6] . Importantly, Yang et al. [7] reported that Orai1 calcium channels are critical for breast tumor cell migration, invasion and metastasis dissemination. However, little is known about the role of cation non- 814 selective Transient Receptor Potential (TRP) channels in human breast ductal adenocarcinoma (hBDA).
The TRP superfamily is organized into six subgroups according to their sequence homology, the main ones being TRPC for "canonical" (TRPC1 to TRPC7), TRPM for "melastatin" (TRPM1 to TRPM8) and TRPV for "vanilloid" (TRPV1 to TRPV6) [8, 9] . The first correlation between TRP expression and cancer phenotype concerned TRPM1 as a tumor suppressor gene in melanoma [10] . TRPM7 and TRPM8 are overexpressed in pancreatic cancers [11, 12] and TRPC6 in liver, gastric, esophageal and glia cancers [13] [14] [15] [16] . Moreover, TRPV6 and TRPM8 are well known to play a role in prostate cancer, where they could be considered as diagnostic and/ or prognosis markers [17, 18] , and TRPC6 is proposed as a therapeutic target in esophageal carcinoma [19] . Numerous functional studies showed that TRP are involved in different cancer cell processes: TRPC1 in apoptosis resistance in prostate cancer [20] or cell motility in pancreatic cancer and glioma [21, 22] , TRPM8 in cell survival of androgen-sensitive cells [23, 24] , TRPM7 in cell proliferation in pancreatic cancers [12] and cell migration in nasopharyngeal carcinoma [25] , and TRPC6, TRPM8 and TRPV6 in cell proliferation of different cancer cells [11, 13, 14, 16, [26] [27] [28] .
However, few studies have investigated TRP in human breast cancer. We have previously demonstrated that TRPC6 and TRPM7 are overexpressed in hBDA at both protein and mRNA levels, and their functional expression was recorded in the MCF-7 cancer cell line and human breast cancer epithelial (hBCE) cells isolated from surgical resection [29, 30] . We also reported that TRPM8 expression is regulated by estrogens in breast cancer cells and tissues [31] . Other groups demonstrated that TRPC6 and TRPV6 expression increased in both breast cancer tissues and cell lines, and that both TRPC6 and TRPV6 regulated cell proliferation [26, 32] . In the present paper, we first identified TRPC, TRPM and TRPV subfamily expression in hBDA as well as in hBCE and MCF-7 cells. We also investigated TRPC1, TRPC6, TRPM7, TRPM8 and TRPV6 expression and their clinicopathological significance in hBDA. Finally, we focused on TRPV6 involvement in cell migration and invasion in the highly metastatic MDA-MB-231 cell line.
Materials and Methods

Tissues samples
Tissues samples were used with the agreement of patients treated by surgery in the University Hospital of Amiens (Picardie, France). Experiments on human tissues were approved by the Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Picardie (CCPPRBP, Amiens, France).
Histological examination was performed by a pathologist on paraffin-embedded sections after hematoxylin-phloxinsaffron staining. The hBDA were classified according to the Scarff, Bloom and Richardson (SBR) histoprognosis grading system, based on cell differentiation, nuclear polymorphism and mitotic activity: Grade I (well-differentiated), Grade II (moderately-differentiated) and Grade III (poorly-differentiated). Tumor size ( 2 cm, > 2 cm) and Ki67 staining ( 10%, > 10% of the cells) were evaluated separately by a pathologist. Among the 59 samples used in this study, 19 were Grade I, 17 were Grade II, and 23 were Grade III; 24 samples presented a Ki67 10% and 23 were > 10%; 32 samples presented a tumor size 2 cm and 22 were > 2 cm.
Qualitative and real-time RT-PCR
RNA extraction was performed using the standard Trizolphenol-chloroform protocol for hBCE cells and cell lines, or the RNAeasy Micro Kit (Qiagen) for tissues (20 software 3.5 (Roche) using the second derivative maximum method, and exported into the RelQuant ® software (Roche). The results were normalized and expressed as TRP/μg RNA ratio for human tissues or TRP/ -actin for laser capture microdissection experiments according to the Pfaffl method as previously described [33] .
Immunohistochemistry
Immunohistochemical studies were performed using the indirect immuno-peroxidase staining technique on the paraffinembedded material with a Ventana Benchmark XT instrument (Ventana Medical Systems, Roche Diagnostics) and a hematoxylin counterstain as previously described [29] . The sections were incubated with anti-TRPC6 or -TRPM7 antibody (Chemicon, 1/300), anti-TRPC1 or -TRPV6 antibody (Santa Cruz, 1/200 and 1/400) or anti-TRPM8 antibody (Abcam, 1/1500). Negative controls were performed by omitting the primary antibodies, and the specificity of these antibodies was reported in previous studies [29] [30] [31] [34] [35] [36] [37] .
Immuno-staining levels in the epithelial cells were determined by subjective visual scoring of the brown stain under optical microscopy. Scoring levels were: 0= absence of stain-ing; 1= weak; 2= moderate; and 3= strong staining intensity.
Laser capture microdissection (LCM)
Frozen hBDA tissues were sectioned at 60 μm using a cryostat, and placed on PALM membrane slides (PENmembrane, Zeiss). The slides were fixed in ethanol and rapid hematoxylin/eosin staining (Sigma) was used to identify the different types of cells, before collecting the epithelial cells from invasive and non-invasive ductal areas using a PALMZeiss Micro-Beam LCM system.
Total RNA of the microdissected samples was then isolated using the RNAeasy Micro Kit (Qiagen), and reversetranscribed into cDNA with the MultiScribeTM Reverse Transcriptase (Applied Biosystems).
Cell culture
The non metastatic MCF-7 (ATCC ® : HTB-22 TM ) and highly metastatic MDA-MB-231 (ATCC : HTB-26™) cells were grown in Eagle's Minimum Essential Medium supplemented with 5% fetal calf serum (FCS), 2 mM L-glutamine, 0.06% Hepes buffer, 50 IU/ml of penicillin and 50 μg/ml of streptomycin.
Small interfering RNA silencing
Cell transfection was performed using the nucleofection technique (Nucleofactor ® device, Lonza Group Ltd). Human TRPV6 ON-TARGETplus SMART (sequence: 5'-CTGCATGTCAGAGCACTTTAA(dTdT)-3') was used to knockdown TRPV6 expression (siTRPV6), and a functional noncoding siRNA (siControl) was used as negative control. Both siTRPV6 and siControl were purchased from Dharmacon Research Inc.
Proliferation assays
Cells were seeded in 35-mm Petri dishes at a density of 1.10 5 cells after cell transfection and were incubated for further 48 h. Cell viability was assessed by the methylthiazole tetrazolium (MTT) salt assay as previously described [33] . Results are expressed as the percent absorbance relative to the siControl condition.
Migration and invasion assays
Migration tests were performed in 8-μm pore size polyethylene terephtalate membrane cell culture inserts (BD Table 1 
Statistics
2 tests were carried out with the GraphPad software to estimate the correlation between TRP overexpression and hBDA clinical parameters. A correlation was considered significant when P<0.05. Data for PCR quantification, TRPV6 staining score, proliferation, migration and invasion assays are presented as mean ± S.E.M, and statistical analysis was done using a Student's t-test or a non-parametric Mann-Whitney test when the normality test failed (* p<0.05; ** p<0.01, *** p<0.001) with the SigmaStat 3.01a software (Systat Software, Inc.).
Results
TRP mRNA expression pattern in breast cancer tissues and cells
PCR screening of TRPC members revealed the presence of TRPC1, TRPC3 and TRPC6 transcripts in hBCE cells, TRPC1 and TRPC6 in MCF-7 cells, and the four TRPC members in hBDA (Fig. 1A) . As previously described, TRPC1 and TRPC6 were expressed with their splice variant TRPC1A and TRPC6 [28, 38, 39] . For the TRPM family, TRPM7 was detected in all the samples whereas TRPM6 was only expressed in MCF-7 cells (Fig. 1B) . TRPM8 was expressed in both hBDA and MCF-7 cells (Fig. 1B) . Finally, all the TRPV family members were detected in the three models, except for TRPV5 which is not detected in hBCE cells (Fig. 1C) .
TRP protein expression in hBDA
To study the protein expression in human tissues by immunohistochemistry, we focused on TRPC1, TRPC6, TRPM7, TRPM8 and TRPV6 which are expressed in our models, and which are well known to be involved in other cancers. We observed a strong cytosolic staining in cancer epithelial cells using specific antibodies (Fig. 2A3-E3 ). The immunostaining was stronger when compared to their neighboring morphologically non-malignant cells which showed a low signal intensity in the ductular units, particularly in the cytosol of the epithelial cells (Fig. 2A2-E2 ) and also in periductal and myoepithelial cells for TRPM8 (Fig. 2D2) .
To quantify the TRP immunostaining, the brown stain level was determined by visual scoring and both tumor and adjacent non-tumor tissues were compared. Using this score system, we found higher TRP expression in tumoral tissue in 52.2% of patients for TRPC1 (23/44), 78% for TRPC6 (32/41), 57.7% for TRPM7 (15/26), 70% for TRPM8 (21/30) and 44.1% for TRPV6 (26/59). We then investigated the mRNA expression of these five TRP in human tissues using real-time PCR and observed a Dhennin-Duthille/Gautier/Faouzi/Guilbert/Brevet/Vaudry/Ahidouch/ Sevestre/Ouadid-Ahidouch Fig. 1 . Expression pattern of TRP channels in human breast epithelial cancer cells and breast cancer tissue. mRNA expression of human TRPC (A), TRPM (B) and TRPV (C) in breast ductal adenocarcinoma (hBDA), breast cancer epithelial primary culture (hBCE) and MCF-7 cells. The PCR products were obtained using the primers described in Table 1 on three independent tissues or cells samples, and the most representative experiment was showed. Water was used as negative control.
Cell Physiol Biochem 2011; 28:813-822 higher expression (expression fold 2) in tumoral tissue than in the paired non-tumoral one in 50% of the 10 tested patients for TRPC1 (Fig. 3A) , 70% for TRPC6 (Fig. 3B) , 50% for TRPM7 (Fig. 3C) , 80% for TRPM8 (Fig. 3D),   Fig. 2 . Overexpression of TRP channels in breast adenocarcinoma. Typical staining of human breast tissue with anti-TRPC1 (A), anti-TRPC6 (B), anti-TRPM7 (C), anti-TRPM8 (D) and anti-TRPV6 (E) antibodies. Examples of a higher expression level of these TRP channels in adenocarcinoma (A3, B3, C3, D3, E3) than in their non-tumoral counterparts (A2, B2, C2, D2, E2) (magnification x200). No staining in the same non-tumoral (A1, B1, C1, D1, E1) and tumoral (A4, B4, C4, D4, E4) fields when the primary antibody was omitted, demonstrating the specificity of the different antibodies. and 60% for TRPV6 (Fig. 3E) . The high fold-induction observed for TRPM8 channel is due to the very low TRPM8 transcript level in non-tumoral tissue. The realtime PCR results are in concordance with those obtained in immunohistochemistry.
Correlations between TRP protein expression and clinical parameters
The overexpression of TRP in breast cancer compared to the normal mammary gland suggests an involvement of these channels in the pathophysiology of this disease, which might be linked to pathologic parameters. To test this hypothesis, statistical quantifications were performed and parameters relative to the adenocarcinoma proliferative status, (histological grades I and III, Ki67 proliferative marker and tumor size) were analyzed. We have already highlighted that TRPM7 was overexpressed mainly in hBDA presenting high tumor grade associated with high Ki67 (> 10%) or with a large tumor size (> 2 cm) [30] . In the present study, among the TRP overexpressing samples, we interested us with the grades I and III samples and we found that TRPM8 was overexpressed mainly in grade I cancer tissues presenting low Ki67 (55.6% of the samples, Dhennin-Duthille/Gautier/Faouzi/Guilbert/Brevet/Vaudry/Ahidouch/ Sevestre/Ouadid-Ahidouch n=5/9, p=0.0177) or small tumor size (60% of the samples, n=6/10, p=0.0112), while TRPC1 was mainly overexpressed in the small grade I tumors (41.7% of the samples, n=5/12, p=0.0384) ( Table 2 ). However, there was no correlation between either TRPC6 or TRPV6 and the different proliferative parameters (Table 2 ). In addition, no association was found between TRP expression and age or lymph node metastasis (data not shown). These results suggest that TRPC1 and TRPM8 are more frequently overexpressed in small and low proliferative tumors, while TRPM7 channels are correlated with large and highly proliferative tumors. We also analyzed the expression of all these TRP related to the invasive status by comparing the staining levels in the cancer epithelial cells of the ducts (called non-invasive areas) or growing outside the ducts to form clusters (called invasive areas). Statistical analysis indicated that only TRPV6 presented a higher expression in invasive areas than in non-invasive areas for 93.3% of the tested tissues (n=15, Table 3 , Fig. 4A ). Indeed, on the 15 samples presented both invasive and non-invasive areas, the staining score showed a weak staining in non-invasive cells (score 1.5 ± 0.2, p<0.001) and a strong staining in invasive cells (score 2.7 ± 0.1) (Fig. 4B) . Moreover, the (2) from noninvasive (1) areas using laser capture microdissection. Real-time PCR reactions were then carried out on the captured samples, and results were expressed as the average ± SEM of TRPV6/ -actin ratio of four tissue samples analyzed in duplicate. Statistical analysis showed a returned p=0.029. dissociation of the invasive and non-invasive areas using laser capture microdissection followed by mRNA extraction and real-time PCR analysis was then performed in four cancer samples. Figure 4C showed that TRPV6 transcript level was higher in invasive areas than in non-invasive areas (3.5 ± 1.3 fold increase, p<0.05).
Role of TRPV6 in both breast cancer cell migration and invasion
Migration and invasion are important features of malignant cells and their therapeutic inhibition might be critical to avoid metastasis of solid tumors. To fully characterize the abilities of TRPV6 expressing cells, we studied their migration potential and the effect of channel Fig. 5B ). Using the same protocol, MCF-7 cells treated with the TRPV6 siRNA showed a reduction of cell migration by 40% (6.5 ± 0.6 migrating cells) compared to the cells treated with the control siRNA (10.7 ± 0.8 migrating cells; p<0.01; Fig. 5B ). During the time of migration, TRPV6 silencing had no effect on the cell proliferation (Fig. 5C ). Moreover, an invasion assay was also performed using the MDA-MB-231 cells. Results showed that the invasion/migration ratio was 33 ± 4% for the siControl (Fig. 5D ). When the TRPV6 was silenced, the invasion/migration ratio was dramatically decreased to 5 ± 1%, (Fig. 5D, p<0.05 ).
Discussion
Although the relevance of TRP channels in many solid tumors has been extensively studied, their involvement in breast cancer has been poorly investigated. Our study is the first to show the expression pattern of 13 TRP channels in hBDA tissues, hBCE cells and breast cell lines. We observed that TRPC1, TRPC6, TRPM7, TRPM8, and TRPV6 are overexpressed in tumor tissues when compared to the adjacent non-tumor ones. Our findings demonstrate also that TRPC1 and TRPM8 are frequently expressed in the well differentiated and low proliferative breast cancers (grade I, low Ki67), while TRPM7 is mainly overexpressed in the poorly differentiated and highly proliferative ones (grade III, high Ki67). TRPV6 overexpression is strongly associated with the invasive status and regulates both breast cancer cell migration and invasion.
We have already reported that TRPC6 and TRPM7 are functional in both MCF-7 and hBCE cells [29, 30] and that TRPC1 and TRPM7 are required for MCF-7 cell proliferation [30, 39] . Recently, we also reported the expression and regulation of TRPM8 by estrogens in MCF-7 cells [31] . Two other studies have already shown the expression of TRPC4, TRPC6 and TRPV6 in T47D cells [26] as well as TRPC3 and TRPC6 in MCF-7 and MDA-MB-231 cell lines [32] . Here, we demonstrate that TRPC, TRPM and TRPV channels are expressed in the primary epithelial cells as well as in breast adenocarcinoma tissues and in the MCF-7 cell line, except for TRPC3 and TRPC7 in MCF-7 cells, and for TRPC7, TRPM6, TRPM8 and TRPV5 in hBCE cells. In contrast to our findings, Aydar et al. have not detected TRPC1 and TRPC7 in both MCF-7 cells and breast cancer tissues [32] . Their study is based on the analysis of three nontumor tissues compared to four tumor samples, whereas 26 up to 59 specimens of hBDA are studied here, with the non-tumor tissue systematically dissected at distance from the tumor in the same patient.
The expression of ion channels has been proposed as a tool for diagnostic, prognostic and/or therapeutic issues of several diseases [40, 41] . In cancer, TRPV6 and TRPM8 have been proposed as markers of prostate cancer outcome [17, 18, 42] and TRPC6 as a novel therapeutic target for esophageal carcinoma [19] . In breast cancer, our team has demonstrated that TRPM7 is overexpressed in grade III large tumors with a high proliferative index, and proposed TRPM7 as a proliferative marker [30] . Here, we found a high frequency expression of TRPC1, TRPC6, TRPM8 and TRPV6 (Table 2) in hBDA tissues. Both TRPM8 and TRPC1 are mainly overexpressed in grade I tumors with a small size. Moreover, the high expression of TRPM8 is also associated with a low proliferative index. The low detection of TRPC1 and TRPM8 channels in hBCE cells would be due to the fact that the epithelial cells are isolated from the large cancer surgery samples.
TRP expression was also analyzed according to the invasive status and we found that only TRPV6 presented a higher staining in invasive areas when compared to the non-invasive areas. Similar results have been previously reported in prostate cancer. Indeed, using in situ hybridization experiments, TRPV6 was detected in invasive cancer prostatic cells and in lymph node metastasis of prostate origin, suggesting that patients with TRPV6 positive tumors have a poor prognosis [43] . Our results in MDA-MB-231 cells, which are highly metastatic, clearly demonstrate that the TRPV6 channel is involved in metastatic process, and not in cell proliferation. Finally, in spite of the high frequency expression of TRPC6 in hBDA samples (78%), no correlation was found between tumor stage, histological type or lymph node metastasis and TRPC6 overexpression.
In summary, we have demonstrated, for the first time, that TRP channels are overexpressed in breast cancer and that the TRPC1, TRPM7, TRPM8 and TRPV6 staining is associated with pathologic parameters, identifying as putative prognostic markers (Fig. 6) . Thus, TRPC1 and TRPM8 may be considered as good prognosis markers of well-differentiated tumors (Fig. 6A ), TRPM7 as a proliferative marker of poorly-differentiated tumors (Fig. 6A ) and TRPV6 as a poor prognosis marker of aggressive cancers (Fig. 6B) . We believe that our data justify further studies to qualify these TRP as a target for clinical applications.
